ReviewMicroorganisms2025
HIV, Viral Hepatitis, and Schistosomiasis Association with Liver Cancer: A Systematic Review.
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Liver cancer is a notable global health concern, with several infections contributing to its etiology. This systematic review investigates the roles of HIV, viral hepatitis, and schistosomiasis in the development of liver cancer, particularly hepatocellular carcinoma. This systematic review was registered under PROSPERO with the reference: CRD42024566941. A comprehensive literature search was conducted using various databases (PubMed, ScienceDirect, Google Scholar, Scopus, and Web of Science) to identify studies examining the association between HIV, viral hepatitis, and schistosomiasis with hepatocellular carcinoma. The inclusion criteria were studies published in English between the years 2000 and 2025 that primarily explored the association and process through which HIV, viral hepatitis, and schistosomiasis trigger hepatocarcinogenesis. Data retrieval and quality assessment were conducted independently by all co-authors. Overall, 31 studies were deemed relevant to this systematic review. Findings indicate that HIV-associated immunosuppression significantly increases the risk of HCC, with one study reporting a 70% increased incidence among its cohort, and another study noting an 87% increase in HCC-related mortality. Among viral hepatitis cases, one study reported that 86% of HCC infections were attributed to HBV, while HCV genotype 3 was associated with a 68.8% mortality rate in HCC patients. For schistosomiasis, a study showed that 8.1% of schistosomiasis patients with portal vein thrombosis developed HCC. No studies were identified on the association of liver cancer with simultaneous multi-infection by HIV, viral hepatitis, and schistosomiasis. These results underscore the necessity for targeted interventions and integrated strategies to prevent and treat single and concurrent infections that could accelerate infection-associated liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.